CYRAMZA Drug Profile

Summary for Tradename: CYRAMZA

High Confidence Patents:	2
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for CYRAMZA

Recent Clinical Trials for CYRAMZA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Universitaire Ziekenhuizen KU Leuven	PHASE2
Taipei Veterans General Hospital, Taiwan	PHASE1
China Medical University Hospital	PHASE1

See all CYRAMZA clinical trials

Pharmacology for CYRAMZA

Mechanism of Action	VEGFR2 Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Receptor 2 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CYRAMZA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CYRAMZA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	7,498,414	2023-03-04	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	8,057,791	2028-09-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for CYRAMZA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	10,111,968	2036-08-10	Patent claims search
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	10,189,822	2036-03-15	Patent claims search
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	10,220,072	2037-12-06	Patent claims search
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	10,227,328	2036-02-02	Patent claims search

International Patents for CYRAMZA

Country	Patent Number	Estimated Expiration
Germany	60333554
Denmark	1916001
Hong Kong	1118229
Slovenia	1916001

Supplementary Protection Certificates for CYRAMZA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C01916001/01	Switzerland		PRODUCT NAME: RAMUCIRUMAB; REGISTRATION NO/DATE: SWISSMEDIC 65206 29.10.2015
2015C/027	Belgium		PRODUCT NAME: RAMUCIRUMAB; AUTHORISATION NUMBER AND DATE: EU/1/14/957 20141223
15C0034	France		PRODUCT NAME: RAMUCIRUMAB; REGISTRATION NO/DATE: EU/1/14/957 20141223
2015/026	Ireland		PRODUCT NAME: RAMUCIRUMAB; REGISTRATION NO/DATE: EU/1/14/957 20141219

Market Dynamics and Financial Trajectory for CYRAMZA (Ramucirumab)

Last updated: February 19, 2026

What is the current market position of CYRAMZA (Ramucirumab)?

CYRAMZA (ramucirumab) is a monoclonal antibody developed by Eli Lilly, approved by the FDA in 2014. It targets vascular endothelial growth factor receptor-2 (VEGFR-2), inhibiting angiogenesis. The drug is marketed for various cancers, including gastric, non-small cell lung, and hepatocellular carcinoma.

As of 2023, CYRAMZA operates in a competitive landscape dominated by biologics targeting angiogenesis and immune pathways. Its revenues have shown a mixed trend due to regional approvals and reimbursement policies and competition from other anti-angiogenic agents like bevacizumab and ramucirumab biosimilars.

How does the competitive landscape impact CYRAMZA’s market share?

The drug faces competition from biosimilars introduced in larger markets, notably in Europe and the U.S., following patent expirations. Several biosimilars for ramucirumab are in development or filed for approval, which could affect pricing and market share.

Key competitors include:

• Bevacizumab (Avastin)
• Aflibercept (Eylea)
• Ramucirumab biosimilars (e.g., BI 695502 by Boehringer Ingelheim)

In regions with generic entry, pricing pressures reduce profit margins, and market penetration may decline unless new indications or combination therapies strengthen usage.

What are the primary revenue streams and growth drivers for CYRAMZA?

The main revenue sources include:

• Gastric and gastroesophageal junction cancers
• Non-small cell lung cancer
• Hepatocellular carcinoma

Growth drivers:

• Expansion into additional indications, such as ovarian or colorectal cancers
• Increased adoption due to positive trial outcomes
• Higher treatment rates in regional markets with expanding cancer care infrastructure

In 2022, Eli Lilly reported revenues exceeding $100 million globally from CYRAMZA, representing a slight decline from peak years due to pricing pressures and regional access challenges (Eli Lilly, 2023).

How do regional policies influence CYRAMZA’s financial outlook?

Pricing and reimbursement policies significantly impact revenue generation. The U.S. reimbursement environment favors high-cost biologics with proven survival benefits, but continued pressure to contain healthcare costs could limit pricing power.

European markets face stricter pricing controls, with some regions negotiating volume-based discounts, affecting margins. Emerging markets have limited reimbursement, relying on public health initiatives or patient assistance programs to sustain sales.

What is the pipeline outlook and how might new data influence the trajectory?

Ongoing trials explore combination therapies with immune checkpoint inhibitors for lung and gastric cancers, potentially expanding CYRAMZA’s label and sales. Positive trial results can:

• Enable label expansion
• Support higher pricing
• Increase adoption in frontline treatments

Conversely, negative or inconclusive trial results could diminish the drug’s relevance and restrict growth.

What are the key financial risks and opportunities?

Risks:

• Patent expirations and biosimilar competition could reduce market dominance
• Reimbursement variability across regions complicates revenue stability
• Adoption delays in new indications slow revenue growth

Opportunities:

• New indication approvals, especially in combination therapies
• Market expansion into emerging economies
• Cost efficiencies in production and distribution

What are the projected revenue trends for the next five years?

Year	Estimated Revenue (USD millions)	Notes
2023	100	Based on current market share, minor decline expected
2024	95	Competition intensifies, pricing pressures remain
2025	90	Pipeline approvals and label expansions may stabilize revenues
2026	85	Biosimilar entry impacts affordability and sales
2027	80	Continued market share erosion unless new uses materialize

Summary

CYRAMZA’s financial trajectory faces headwinds from biosimilar competition and regional reimbursement policies. Growth depends on approval of new indications, combination regimens, and expansion into emerging markets. Price sensitivity and patent expiration risk erode margins, but pipeline development offers potential for moderate stabilization or modest growth.

---

Key Takeaways

• CYRAMZA’s revenues peaked in the early 2020s but are declining due to biosimilar competition and market saturation.
• Regional reimbursement policies heavily influence sales, with the U.S. providing the most favorable environment.
• The pipeline's progress in combination therapies or second-line indications drives future sales opportunities.
• Biosimilar entry and patent expirations will likely reduce pricing power, pressuring margins.
• Expansion into emerging markets and new indications remains critical for sustained growth.

FAQs

1. Which cancers does CYRAMZA currently treat?
CYRAMZA is approved for gastric or gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and hepatocellular carcinoma.

2. How does biosimilar competition affect CYRAMZA’s market share?
Biosimilars lower prices, threaten market share, and can erode margins, especially in regions where patent protections expire.

3. Are there upcoming approvals that could boost CYRAMZA’s revenues?
Yes, ongoing trials for combination therapies in lung and gastric cancers could expand indications if successful.

4. How significant are reimbursement policies for CYRAMZA's sales?
Reimbursement policies strongly influence sales, especially in Europe and emerging markets, where price controls and access limits exist.

5. What risks could derail CYRAMZA’s financial outlook?
Patent expirations, biosimilar entry, unfavorable trial outcomes, and pricing pressures pose risks.

---

References

1. Eli Lilly. (2023). Annual Report 2022. Retrieved from https://investor.lilly.com
2. U.S. Food and Drug Administration. (2014). Fy20014: Approved Drugs. Retrieved from https://www.fda.gov
3. Grand View Research. (2022). Cancer biologics market analysis. Retrieved from https://www.grandviewresearch.com